文献速递神经肿瘤

恶性胶质瘤术中5-氨基乙酰丙酸识别与切除相关肝损伤风险的评估

Evaluation of the risk of liver damage from the use of 5-aminolevulinic acid for intra-operative identification and resection in patients with malignant gliomas.
PubMed 文献 · Acta Neurochir (Wien) · 2016-11-10

回顾性分析2012年9月至2014年9月哥本哈根大学医院Rigshospitalet接受5-氨基乙酰丙酸(5-ALA)引导手术的99例成人恶性胶质瘤患者,术前给予20 mg/kg体重5-ALA,评估术前术后丙氨酸氨基转移酶、天冬氨酸氨基转移酶、γ-谷氨酰转移酶和淀粉酶水平。50例出现一次或多次术后肝酶暂时性升高,术后均值未升高(女性γ-谷氨酰转移酶短暂升高除外),未观察到肝损害或肝衰竭临床征象,作者认为可取消常规血检但已知肝损害患者仍需谨慎。

要点

  • 99例成人中50例出现一次或多次术后肝酶暂时性升高。
  • 术后均值未升高,仅女性γ-谷氨酰转移酶短暂升高。
  • 未观察到肝损害或肝衰竭临床征象。

核心结论

  • 作者认为5-ALA给药或5-ALA、麻醉与肿瘤切除联合作用可引起轻度可逆的肝酶升高,因此改变监测方案似乎安全,常规血检可取消,但已知肝损害患者仍需谨慎。

研究设计与样本

  • 回顾性研究纳入2012年9月至2014年9月哥本哈根大学医院Rigshospitalet接受5-ALA引导手术的所有患者,所有患者术前接受20 mg/kg体重5-ALA,评估男女患者术前术后丙氨酸氨基转移酶、天冬氨酸氨基转移酶、γ-谷氨酰转移酶和淀粉酶水平,99例成人符合纳入标准。

主要发现

  • 99例成人中50例出现一次或多次术后肝酶暂时性升高。
  • 术后均值未升高,仅女性γ-谷氨酰转移酶水平短暂升高。
  • 未记录到肝损害或肝衰竭临床征象。

临床怎么用

  • 作者认为改变监测方案似乎安全,常规血检可取消,但已知肝损害患者仍需谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical efficacy of 5-aminolevulinic acid (5-ALA) for fluorescence-guided surgery of malignant gliomas is evident from several studies; however, as post-operative elevations of liver enzymes have been seen, there is a potential risk of liver damage upon administration. The aim of the present study was to assess the potential risk of liver damage and investigate liver enzyme reactions of patients going through 5-ALA-guided operations to improve the monitoring of their operations. METHODS: A retrospective study of all patients undergoing 5-ALA-guided surgery during a 2-year period (September 2012-September 2014) at the University Hospital of Copenhagen, Rigshospitalet, was conducted. All patients received a pre-operative dose of 20 mg/kg bodyweight 5-ALA. The pre- and post-operative enzyme levels of alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase and amylase of both men and women, respectively, were evaluated. RESULTS: Ninety-nine adults met the inclusion criteria. Fifty patients had one or multiple temporary post-operative elevations of their liver enzymes. The mean post-operative values were not increased, except for a brief elevation of gamma-glutamyltransferase levels in women. No registrations of liver impairment or clinical signs of liver failure were observed. CONCLUSIONS: The findings suggest that the administration of 5-ALA or the combined effect of 5-ALA, anaesthesia and tumour resection can cause a mild and reversible elevation in liver enzymes. It therefore appears safe to change the regime of monitoring. Routine blood samples are thus abolished, though caution remains necessary in patients with known liver impairment.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Offersen CM, Skjoeth-Rasmussen J. Evaluation of the risk of liver damage from the use of 5-aminolevulinic acid for intra-operative identification and resection in patients with malignant gliomas. Acta Neurochir (Wien). 2016. PMID: 27832337. doi:10.1007/s00701-016-3014-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。